Carriers are identified through a combination of laboratory testing, family history analysis, and epidemiological investigation, depending on whether the term refers to a genetic carrier of a hereditary condition or an asymptomatic carrier of an infectious disease. The specific method used has evolved dramatically over the past century, from painstaking detective work tracing outbreaks back to a single person, to modern DNA sequencing that can scan hundreds of genes in a single test with accuracy rates above 99.9%.
Genetic Carriers: Screening With DNA Sequencing
A genetic carrier is someone who has one copy of a recessive gene mutation. They don’t develop the condition themselves, but they can pass it to their children. If both parents carry the same mutation, each pregnancy has a 25% chance of producing a child with the disease. Identifying these carriers before or during pregnancy is the goal of reproductive genetic carrier screening.
The earliest screening panels used targeted genotyping, an array-based technology that checks for hundreds or thousands of already-known DNA variants using specially designed probes. This approach works well for well-studied mutations but misses novel or rare variants entirely. It was a reasonable starting point, but it had a ceiling.
Next-generation sequencing (NGS) changed the landscape. Rather than looking for a short list of known mutations, NGS reads large stretches of genetic code and can detect both known and previously unknown alterations simultaneously. A 2022 validation study compared NGS against two older methods for detecting copy number changes in the gene responsible for spinal muscular atrophy. NGS outperformed both, leading researchers to suggest it could replace multiple older tests, saving time and cost in the process. When sequencing depth exceeds 100-fold (meaning each section of DNA is read more than 100 times), the sensitivity, specificity, and accuracy for detecting single-letter DNA changes all reach 99.9%, with coverage of targeted gene regions at 99.83%.
In practical terms, this means modern expanded carrier screening panels are extremely reliable. A large study of over 3,700 individuals screened for 155 recessive diseases across 147 genes found that 5.34% of couples tested were identified as “at-risk,” meaning both partners carried a mutation in the same gene. The most commonly detected carrier states were for Wilson disease (2.89% of individuals), a type of hereditary hearing loss called DFNB4 (2.09%), and spinal muscular atrophy (2.06%).
Which Conditions Are Routinely Screened
The American College of Obstetricians and Gynecologists recommends universal screening for three conditions: cystic fibrosis, spinal muscular atrophy, and hemoglobinopathies (a group of blood disorders that includes sickle cell disease and thalassemia). Beyond these three, additional screening recommendations have traditionally been based on ethnicity, since certain mutations cluster in specific populations.
That ethnicity-based approach is shifting. Both the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors now recommend universal expanded-panel screening, arguing it’s more equitable and catches mutations that ethnicity-based guidelines would miss. ACOG acknowledges expanded panels as an acceptable option but hasn’t yet declared them the standard of care, which leaves some inconsistency in what’s offered from one clinic to the next.
Hereditary Cancer Carriers
Identifying carriers of hereditary cancer syndromes like BRCA1/2 (linked to breast and ovarian cancer) or Lynch syndrome (linked to uterine, colorectal, and ovarian cancer) follows a different path. It starts not with a universal screening panel but with a detailed risk assessment built from personal and family history.
Clinicians gather information from both sides of the family, including pathology reports, imaging records, and confirmation of cancer diagnoses through medical records or death certificates. Asking both male and female relatives about maternal and paternal ancestry matters because cancer-predisposing mutations can be inherited through either parent, even if the parent themselves never developed cancer. All women with a personal history of epithelial ovarian cancer, or a first-degree relative with it, are referred directly for genetic counseling and testing. Women with endometrial or colon cancer are evaluated for hereditary cancer risk as well, since Lynch syndrome accounts for most cases of hereditary uterine and colorectal cancer.
Infectious Disease Carriers: Tracing the Invisible
An asymptomatic infectious disease carrier is someone who harbors and spreads a pathogen without showing symptoms. Identifying these individuals is fundamentally harder than genetic screening because there’s no universal test you take before you become a carrier. Instead, they’re typically found through reactive investigation after cases appear.
During the COVID-19 pandemic, asymptomatic carriers were identified through five main routes: monitoring close contacts of confirmed cases during their observation period, investigating cluster outbreaks through active testing, tracing backward from a patient to find their likely source of infection, screening people with recent travel to high-transmission areas, and opportunistic screening during broader epidemiological surveys. Each of these relies on testing people who have no reason to suspect they’re infected.
The laboratory side of carrier detection for infectious diseases uses different markers than genetic screening. Antibody testing (looking for the immune system’s response to an infection) reveals a distinctive pattern in asymptomatic carriers. Both IgM and IgG antibodies, including neutralizing antibodies, are significantly lower in asymptomatic individuals compared to people who had symptoms and recovered. In one study, 90.4% of asymptomatic carriers showed declining antibody levels over just a two-week period. Their immune systems also showed lower B-cell counts, fewer antibody-producing cells, and a muted inflammatory response. This weaker immune signature makes asymptomatic carriers harder to detect through blood tests alone, which is why direct pathogen detection through methods like PCR remains essential.
The Case That Started It All: Typhoid Mary
The concept of a healthy carrier was essentially unknown before 1907, when a sanitary engineer named George Soper identified Mary Mallon as the first known typhoid carrier in the United States. His method was pure epidemiological detective work. Soper traced seven separate typhoid outbreaks, totaling 26 cases over seven years, to households where Mallon had worked as a cook. By mapping her employment history against the timing and location of each outbreak, he built a case that no other explanation fit. Over the course of her life, 57 cases and three deaths were attributed to her, all while she remained healthy and initially refused to believe she was infectious.
Soper’s investigation is still cited as a landmark in epidemiology because it demonstrated that a person with no symptoms could be a persistent source of disease. That principle now underpins the entire field of carrier identification, from contact tracing during pandemics to routine genetic screening before pregnancy.
What Happens After Identification
For genetic carriers, a positive result triggers a specific sequence. If one partner is found to carry a mutation, the other partner is tested for the same gene. If both carry it, the couple is referred for genetic counseling to discuss reproductive options, which can include preimplantation genetic testing during IVF, prenatal diagnostic testing, or planning for early treatment after birth. Carrier status itself doesn’t change your health, but it reshapes decision-making around having children.
For infectious disease carriers, identification leads to isolation protocols, monitoring for symptom development, and in some cases treatment to reduce the pathogen load even if symptoms never appear. The challenge is that many asymptomatic carriers are never identified at all, particularly in diseases where testing resources are limited or where the carrier state is short-lived.